vemurafenib
vemurafenib: 7 clinical trials tracked.
vemurafenib evidence translation
What we can confirm
7 tracked trials
What it means
What to watch
Prepared research question
What is verified about vemurafenib, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence5 indications · 4 study sponsors
Clinical Trials (7)
Optimization of the Time and Dosage of Vemurafenib in BRAF Positive Juvenile Patients With Refractory Histiocytosis
Primary endpoint: event-free survival
NAUTIKA1: A Multicenter, Phase II, Neoadjuvant and Adjuvant Study of Multiple Therapies in Biomarker-selected Patients With Resectable Stages IB-III Non-small Cell Lung Cancer
Primary endpoint: Tyrosine Kinase Inhibitor (TKI) Cohort: Proportion of Participants With Major Pathologic Response (MPR)
An Open Label, Multicenter Extension Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella B)
Primary endpoint: Number of Participants With Continued Access to Atezolizumab-Based Therapy and/or Comparator Agent(s)
Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas
Primary endpoint: Response Rate
Phase I Study of Escalating Doses of XL888 With Vemurafenib Plus Cobimetinib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma
Primary endpoint: Maximum Tolerated Dose (MTD)
Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Primary endpoint: Objective Response Rate defined as % of participants in a cohort with complete or partial response or with stable disease according to standard response criteria
A Phase II Clinical Trial of Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Patients With Metastatic Melanoma
Primary endpoint: Percentage of Participants With Overall Response (OR)